NCT03132493

Brief Summary

The investigators will be retrospectively review the case note of patients registered in the EAP of Nivolumab. A standard anonymous data collection form will be used to collect data and to analyze it. Patients with advanced Non-Small Cell Lung Cancer previously treated and included in the SPANISH expanded access programme of nivolumab.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
676

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2017

Geographic Reach
1 country

61 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 25, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 27, 2017

Completed
1 month until next milestone

Study Start

First participant enrolled

June 1, 2017

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2018

Completed
Last Updated

November 14, 2018

Status Verified

November 1, 2018

Enrollment Period

6 months

First QC Date

April 25, 2017

Last Update Submit

November 12, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Progression Free survival

    time from inclusion to progression

    At 12 months

Secondary Outcomes (1)

  • Overall Response rate

    At 12 months

Interventions

nivolumab 3 mg/kg as an intravenous infusion every 2 weeks until progression

Also known as: Opdivo

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients eligible for the trial are those treated in the EAP of nivolumab in Spain. The total number of patients to be included will be 1400 from 150 participating sites in Spain (anticipated data)

You may qualify if:

  • Squamous or Non-Squamous, non small cell lung cancer (NSCLC), Stage IIIb/IV (histologically or cytologically confirmed), relapsed after 1 prior platinum-based systemic treatment and who received treatment within the SPANISH expanded access programme of nivolumab (EAP)
  • Alive patients must have signed and dated an IRB/IEC-approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care

You may not qualify if:

  • Alive patients who do not want to sign and date an IRB/IEC-approved written informed consent form
  • Patients who were accepted in the EAP but do not receive treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (61)

Hospital Virgen de los Lirios

Alcoy, Alicante, 03804, Spain

Location

Hospital de Elche

Elche, Alicante, 03202, Spain

Location

Hospital Universitario de Vinalopó

Elche, Alicante, 03293, Spain

Location

Hospital General Universitario de Elda

Elda, Alicante, 03600, Spain

Location

H. Germans Trias i Pujol

Badalona, Barcelona, 08916, Spain

Location

Hospital de Mataró

Mataró, Barcelona, 08304, Spain

Location

Corporació Sanitaria Parc Taulí

Sabadell, Barcelona, 08208, Spain

Location

Consorci Sanitari de Terrassa

Terrassa, Barcelona, 08220, Spain

Location

Hospital Universitari Mútua de Terrassa

Terrassa, Barcelona, 08221, Spain

Location

Hospital de Galdakao

Galdakao, Bizkaia, 48960, Spain

Location

Hospital Universitario de Donostia

Donostia / San Sebastian, Gipuzkoa, 20014, Spain

Location

Centro Oncológico de Galicia

A Coruña, La Coruña, 15009, Spain

Location

Hospital Insular de Gran Canaria

Las Palmas de Gran Canaria, Las Palmas, Spain

Location

Hospital Universitario Fundación Alcorcón

Alcorcón, Madrid, 28922, Spain

Location

Hospital Universitario de Fuenlabrada

Fuenlabrada, Madrid, 28942, Spain

Location

Hospital Severo Ochoa

Leganés, Madrid, 28911, Spain

Location

Hospital Universitario de Móstoles

Móstoles, Madrid, 28935, Spain

Location

Hospital Universitario Infanta Cristina

Parla, Madrid, 28981, Spain

Location

Hospital Universitario Quirón Madrid

Pozuelo de Alarcón, Madrid, Madrid, Spain

Location

Clínica Universitaria de Navarra

Pamplona, Navarre, 31008, Spain

Location

Complejo Hospitalario de Navarra

Pamplona, Navarre, 31008, Spain

Location

Hospital Sant Joan de Reus

Reus, Tarragona, 43204, Spain

Location

Hospital Lluís Alcanyís

Xàtiva, Valencia, 46800, Spain

Location

Hospital de Cruces

Barakaldo, Vizcaya, 48903, Spain

Location

Hospital de Basurto

Bilbao, Vizcaya, 48013, Spain

Location

Hospital Universitario a Coruña

A Coruña, 15006, Spain

Location

Hospital del Mar

Barcelona, 08003, Spain

Location

Hospital Vall d' Hebron

Barcelona, 08035, Spain

Location

H. Universitario Quirón Dexeus

Barcelona, 08036, Spain

Location

Hospital de Sant Pau Y de La Santa Creu

Barcelona, 08036, Spain

Location

H. Althaia

Barcelona, 08243, Spain

Location

Hospital Virgen de la Luz

Cuenca, 16002, Spain

Location

Hospital Dr. Josep Trueta

Girona, 17007, Spain

Location

Hospital Clínico San Cecilio

Granada, 18012, Spain

Location

Hospital de Guadalajara

Guadalajara, 19002, Spain

Location

Complejo Hospitalario de Jaén

Jaén, 23007, Spain

Location

Complejo Asistencial Universitario de León

León, 24071, Spain

Location

Hospital Universitario Lucus Augusti

Lugo, 27003, Spain

Location

Hospital General Universitario Gregorio Marañón

Madrid, 28007, Spain

Location

MD Anderson Cancer Center

Madrid, 28033, Spain

Location

H.U. Puerta de Hierro

Madrid, 28035, Spain

Location

Fundación Jimenez Diaz

Madrid, 28040, Spain

Location

Hospital Clínico San Carlos

Madrid, 28040, Spain

Location

Hospital Universitario Infanta Sofía

Madrid, 28703, Spain

Location

H. Carlos Haya

Málaga, 29010, Spain

Location

Hospital Universitario Virgen de la Victoria

Málaga, 29010, Spain

Location

H. Morales Messeguer

Murcia, 30008, Spain

Location

Hospital Clínico Universitario Virgen de la Arrixaca

Murcia, 30120, Spain

Location

Hospital Son Espases

Palma de Mallorca, 07010, Spain

Location

H. Son Llàtzer

Palma de Mallorca, 07198, Spain

Location

Hospital Clinico de Salamanca

Salamanca, 37007, Spain

Location

Hospital Nuestra Señora Candelaria

Santa Cruz de Tenerife, 38010, Spain

Location

Hospital Virgen del Rocío

Seville, 41013, Spain

Location

Instituto Valenciano de Oncología

Valencia, 46009, Spain

Location

Hospital General de Valencia

Valencia, 46014, Spain

Location

Hospital Dr. Peset

Valencia, 46017, Spain

Location

Hospital de Sagunto

Valencia, 46500, Spain

Location

Hospital La Fe

Valencia, Spain

Location

Hospital Clínico Universitario de Valladolid

Valladolid, 47003, Spain

Location

H. Miguel Servet

Zaragoza, 50009, Spain

Location

Hospital Universitario de Áraba

Vitoria-Gasteiz, Áraba, 01009, Spain

Location

Related Links

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Nivolumab

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulins

Study Officials

  • Delvys Rodríguez, MD, PhD

    Hospital Universitario Insular de Gran Canaria

    PRINCIPAL INVESTIGATOR
  • Margarita Majem, MD, PhD

    Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 25, 2017

First Posted

April 27, 2017

Study Start

June 1, 2017

Primary Completion

December 1, 2017

Study Completion

September 15, 2018

Last Updated

November 14, 2018

Record last verified: 2018-11

Data Sharing

IPD Sharing
Will not share

Locations